[
  {
    "ts": "2026-01-06T10:30:00+00:00",
    "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
    "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
    "url": "https://www.wsj.com/health/pharma/big-pharma-has-more-going-for-it-than-obesity-drugs-35ffd102?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "718b31ea-161c-37e0-b9a9-30d517b0adda",
      "content": {
        "id": "718b31ea-161c-37e0-b9a9-30d517b0adda",
        "contentType": "STORY",
        "title": "Big Pharma Has More Going for It Than Obesity Drugs",
        "description": "",
        "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
        "pubDate": "2026-01-06T10:30:00Z",
        "displayTime": "2026-01-06T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/718b31ea-161c-37e0-b9a9-30d517b0adda/big-pharma-has-more-going-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/e4b5dcc738daaf9952e09fd2749449f5",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7RMo0RAoQIXBecVowGWgxA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/e4b5dcc738daaf9952e09fd2749449f5.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0b65xm2vuQmoOxj8Df4WNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/e4b5dcc738daaf9952e09fd2749449f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/big-pharma-has-more-going-for-it-than-obesity-drugs-35ffd102?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T09:40:00+00:00",
    "headline": "The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson",
    "summary": "Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.",
    "url": "https://finance.yahoo.com/news/zacks-analyst-blog-eli-lilly-094000185.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "5342e76f-40d4-391a-a28e-da80e64d0195",
      "content": {
        "id": "5342e76f-40d4-391a-a28e-da80e64d0195",
        "contentType": "STORY",
        "title": "The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson",
        "description": "",
        "summary": "Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.",
        "pubDate": "2026-01-06T09:40:00Z",
        "displayTime": "2026-01-06T09:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-eli-lilly-094000185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-eli-lilly-094000185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ISRG"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T09:34:00+00:00",
    "headline": "Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford",
    "summary": "Pagaya, Eli Lilly and Weatherford have been highlighted in this Investment Ideas article.",
    "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-093400054.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "234c33cd-5548-3d7d-8eaa-89d674ed3a2e",
      "content": {
        "id": "234c33cd-5548-3d7d-8eaa-89d674ed3a2e",
        "contentType": "STORY",
        "title": "Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford",
        "description": "",
        "summary": "Pagaya, Eli Lilly and Weatherford have been highlighted in this Investment Ideas article.",
        "pubDate": "2026-01-06T09:34:00Z",
        "displayTime": "2026-01-06T09:34:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-093400054.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-093400054.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "WFRD"
            },
            {
              "symbol": "PGY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "PLTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T04:33:06+00:00",
    "headline": "2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finance.yahoo.com/news/2-cash-producing-stocks-keep-043306905.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "1f4ddb06-e0fb-355c-a3a2-773863b3387e",
      "content": {
        "id": "1f4ddb06-e0fb-355c-a3a2-773863b3387e",
        "contentType": "STORY",
        "title": "2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore",
        "description": "",
        "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
        "pubDate": "2026-01-06T04:33:06Z",
        "displayTime": "2026-01-06T04:33:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/727a6bbfc0df03ca73137e069e75f3f6",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "UBER Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wygrlfSkoupi0hpmhe.O_g--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/727a6bbfc0df03ca73137e069e75f3f6.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R9LiUKiId062gWopN8aXGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/727a6bbfc0df03ca73137e069e75f3f6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-cash-producing-stocks-keep-043306905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-cash-producing-stocks-keep-043306905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSCI"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UBER"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T13:00:00+00:00",
    "headline": "Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment",
    "summary": "BOSTON, January 06, 2026--Nimbus Therapeutics, LLC (\"Nimbus Therapeutics\" or \"Nimbus\"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (\"Lilly\") to develop a novel oral treatment for obesity and other metabolic diseases.",
    "url": "https://finance.yahoo.com/news/nimbus-therapeutics-announces-research-collaboration-130000326.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "71c481d9-d7d4-381f-9f09-4f921d8923cf",
      "content": {
        "id": "71c481d9-d7d4-381f-9f09-4f921d8923cf",
        "contentType": "STORY",
        "title": "Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment",
        "description": "",
        "summary": "BOSTON, January 06, 2026--Nimbus Therapeutics, LLC (\"Nimbus Therapeutics\" or \"Nimbus\"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (\"Lilly\") to develop a novel oral treatment for obesity and other metabolic diseases.",
        "pubDate": "2026-01-06T13:00:00Z",
        "displayTime": "2026-01-06T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/902cc921431246d14ccd3804173e2b35",
          "originalWidth": 480,
          "originalHeight": 240,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TJj1pEWshrwngf8bvnHklQ--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/902cc921431246d14ccd3804173e2b35.cf.webp",
              "width": 480,
              "height": 240,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ckQKjcedmZzaBI0GknSo9w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/902cc921431246d14ccd3804173e2b35.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nimbus-therapeutics-announces-research-collaboration-130000326.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nimbus-therapeutics-announces-research-collaboration-130000326.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T12:30:27+00:00",
    "headline": "Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss",
    "summary": "Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.",
    "url": "https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "772f1cfe-2b2b-33ba-97c1-abe0e16f3cc2",
      "content": {
        "id": "772f1cfe-2b2b-33ba-97c1-abe0e16f3cc2",
        "contentType": "STORY",
        "title": "Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss",
        "description": "",
        "summary": "Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.",
        "pubDate": "2026-01-06T12:30:27Z",
        "displayTime": "2026-01-06T12:30:27Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/772f1cfe-2b2b-33ba-97c1-abe0e16f3cc2/arrowhead-says-its-gene.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/10c1a05f1de308bdfa56991ef393218d",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GTTamNDY.xTkLNhdAFEHFQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/10c1a05f1de308bdfa56991ef393218d.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wFLjwWqj4ZKHjwdb.mDUAA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/10c1a05f1de308bdfa56991ef393218d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARWR"
            },
            {
              "symbol": "WVE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T14:30:00+00:00",
    "headline": "Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?",
    "summary": "Eli Lilly offers investors safety and growth.",
    "url": "https://www.fool.com/investing/2026/01/06/should-you-buy-eli-lilly-before-it-reaches-1-trill/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "46915a36-1c15-36cf-841b-b08a127b0943",
      "content": {
        "id": "46915a36-1c15-36cf-841b-b08a127b0943",
        "contentType": "STORY",
        "title": "Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?",
        "description": "",
        "summary": "Eli Lilly offers investors safety and growth.",
        "pubDate": "2026-01-06T14:30:00Z",
        "displayTime": "2026-01-06T14:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/8278e3d76f85abf63e07dfd37fd7cf93",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "An investor looks pensively at a computer screen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9Uu.5Pmo1Yt2F_YtLx8bLA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8278e3d76f85abf63e07dfd37fd7cf93.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PQwoyClB7Msi_tqrtWgcbw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/8278e3d76f85abf63e07dfd37fd7cf93.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/06/should-you-buy-eli-lilly-before-it-reaches-1-trill/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-eli-lilly-reaches-1-143000125.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]